Virus-based therapies for colon cancer

Bibliography

• KURUPPU D, TANABE KK: Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther. (2005) 4:524-531. Comprehensive review of viral oncolysis with details on important considerations for development of this therapy.
   Google Scholar
• REID TR, GALANIS E, ABBRUZZESE J et al.: Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biological activity (abstract). Proc. Am. Soc. Chn. Oncol. (2001) 20:549a.
   Google Scholar
• RODRIGUEZ R, SCHUUR ER, LIM HY,HENDERSON GA, SIMONS P(1, HENDERSON DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559–2563.
   PubMed Web of Science ®Google Scholar
• KOOBY DA, CAREW JF, HALTERMAN MW et al.: Oncolytic viral Expert Opin. Biol. Ther (2005) 5(12)1631
   Google Scholar
• •• therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. (1999) 13(11):1325–1334.
   PubMed Web of Science ®Google Scholar
• REINBLATT M, PIN RH, FEDEROFF HJ, FONG Y: Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann. Surg-. (2004) 239(6):892–899; discussion 899–902.
   Google Scholar
• CINATL J JR, MICHAELIS M, DRIEVER PH et al.: Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neop/asia (2004) 6(6):725–735.
   PubMed Web of Science ®Google Scholar
• NAKANO K, TODO T, ZHAO G et ed.: Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J. Gene Med. (2005) 7(5):638–648.
   Google Scholar
• BENNETT JJ, DELMAN KA, BURT BM et al.: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. (2002) 9(10:935–945.
   PubMed Web of Science ®Google Scholar
• FONG Y, JARNAGIN W, GUILFOYLE B et al.: Results of a Phase I, dose-escalating study of the safety, tolerability, and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, NV1020, in subjects with hepatic colorectal metastases. Proc. Am. Soc. Clin. Oncol (2005):abstract 242.
   Google Scholar
• LORENCE RM, ROBERTS MS, GROENE WS et al.: Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. Proc. Am. Assoc. Cancer Res. (2001) 42:2442a.
   Google Scholar
• PECORA AL, RIZVI N, COHEN GI: An intravenous Phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers. Proc. Am. Soc. Clin. Oncol (2001) 20:1009a.
   Google Scholar
• ZAGER JS, DELMAN KA, MALHOTRA S et al.: Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Md. Med. (2001) 7:561–568.
   Google Scholar
• COFFIN RS, HU JC, DAVIS CJ et al.: Results of a Phase I/II clinical trial with OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3099.
   Google Scholar
• MULLEN JT, DONAHUE JM, CHANDRASEKHAR S et al.: Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 101:869–877.
   PubMed Web of Science ®Google Scholar
• WONG RJ, CHAN MK, YU Z et al.: Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. (2004) 10(13):4509–4516.
   PubMed Web of Science ®Google Scholar
• SOVA P, REN XW, NI S et al.: A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. MoL Ther. (2004) 9(4):496–509.
   PubMed Web of Science ®Google Scholar
• LI Y, CHEN Y, DILLEY J et ed.: Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol. Cancer Ther. (2003) 2(10):1003–1009.
   Google Scholar
• HIRASAWA K, NISHIKAWA SG, NORMAN KI,, ALAIN T, KOSSAKOWSKA A, LEE PW: Oncolytic reovirus against ovarian and colon cancer. Cancer Res. (2002) 62(6):1696–1701.
   PubMed Web of Science ®Google Scholar
• TU SP, CUI JT, LISTON P et al.: Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology (2005) 128(2):361–375.
   PubMed Web of Science ®Google Scholar
• •Novel, adenovirally delivered, gene therapy-based approach for causing apoptosis of colon cancer.
   Google Scholar
• AKBULUT H, TANGY, MAYNARD J, ZHANG L, PIZZORNO G, DEISSEROTH A: Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin. Cancer Res. (2004) 10(22):7738–7746.
   PubMed Web of Science ®Google Scholar
• OOSTERHOFF D, OVERMEER RM, DE GRAAF M et al.: Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br. J. Cancer (2005) 92(5):882–887.
   Google Scholar
• SLAVIN-CHIORINI DC, CATALFAMO M, KUDO-SAITO C, HODGE JW, SCHLOM J, SABZEVARI H: Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther. (2004) 11(10):665–680.
   PubMed Web of Science ®Google Scholar
• KASS E, SCHLOM J, THOMPSON J et al.: Induction of protective host immunity to carcinoembryonic antigen (CEA) a self-antigen in CFA transgenic mice, by immunizing with a recombinant vaccinia-CFA virus. Cancer Res. (1999) 59:676–683.
   PubMed Web of Science ®Google Scholar
• TSANG KY, ZAREMBA S, NIERODA CA et al.: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CFA vaccine. J. Nail Cancer Inst. (1995) 87:982.
   PubMed Web of Science ®Google Scholar
• MARSHALL J, HAWKINS MJ, TSANG KY et al.: Phase I study in cancer patients of a replication-defective avipox recominbant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol (1999) 17:332–337.
   PubMed Web of Science ®Google Scholar
• ••State-of-the-art clinical trial of aprime-boost poxvector-based vaccine for therapy of CEA-expressing malignancies, including colon cancer. This paper illustrates many of the challenges and opportunities of viral vector-based vaccines.
   Google Scholar
• ZHU MZ, MARSHALL J, COLE D, SCHLOM J, TSANG KY: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. (2000) 6:24–33.
   PubMed Web of Science ®Google Scholar
• VON MEHREN M, ARLEN P, TSANG KY et al.: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CFA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. (2000) 6:2219–2228.
   Google Scholar
• VON MEHREN M, DAVEY M, MCLAUGHLIN S et al.: Phase I Study of Vaccine Therapy with ALVAC-CEA B7.1 and GM-CSF (G) in Patients (PTS) with Advanced CEA-Expressing Cancers. Proc. Am. Soc. Clin. Oncol (2000) 19:480a (abstract 1883).
   Google Scholar
• VON MEHREN M et al.: The Influence ofgranulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. (2001) 7:1181–1191.
   Google Scholar
• HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49:504–514.
   Google Scholar
• MARSHALL J, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18:3964–3974.
   PubMed Web of Science ®Google Scholar
• SLACK R, LEY L, CHANG P et al.: Association between CEA-specific T cell responses (TCR) following treatment with Vaccinia CEA (V) and Alvac CEA (A) and survival in patients with CEA bearing cancers. Proc. Am. Soc. Clin. Oncol. (2001) 20:272a (abstract 1086).
   Google Scholar
• MARSHALL JL, GULLEY JL, ARLEN PM et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. (2005) 23 (4): 720–731.
   PubMed Web of Science ®Google Scholar